Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-12-17 07:30 |
INNATE PHARMA (Euronext Paris: FR0010331421 - IPH) : Premier patient traité dan…
|
French | 34.0 KB | ||
| 2012-12-17 07:30 |
INNATE PHARMA (Euronext Paris: FR0010331421 - IPH): First patient treated in th…
|
English | 32.4 KB | ||
| 2012-12-11 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce la publication de…
|
French | 32.9 KB | ||
| 2012-12-11 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) updates on four early cli…
|
English | 32.8 KB | ||
| 2012-11-23 07:30 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) publie sa lettre aux acti…
|
French | 1.1 MB | ||
| 2012-11-23 07:30 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces that its newsle…
|
English | 1.1 MB | ||
| 2012-11-14 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce un chiffre d’affa…
|
French | 69.7 KB | ||
| 2012-11-14 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces revenue of 8.0 …
|
English | 36.9 KB | ||
| 2012-11-08 20:31 |
Rapport financier semestriel au 30 juin 2012
|
French | 180.2 KB | ||
| 2012-11-07 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation …
|
French | 78.5 KB | ||
| 2012-11-07 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its second part…
|
English | 77.9 KB | ||
| 2012-10-30 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce qu’un essai clini…
|
French | 40.3 KB | ||
| 2012-10-30 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)today announces that a Pha…
|
English | 38.8 KB | ||
| 2012-09-06 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses r…
|
French | 70.2 KB | ||
| 2012-09-06 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces today its finan…
|
English | 67.5 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
